Entresto?

See the DrugPatentWatch profile for Entresto

What is Entresto, and how does it work?

Entresto (sacubitril/valsartan) is a medication prescribed for the treatment of heart failure with reduced ejection fraction (HFrEF) and left ventricular ejection fraction (LVEF) in adults [1]. It is a combination of two active ingredients, sacubitril and valsartan, which work together to improve the symptoms and outcomes of patients with heart failure.

How does Entresto compare with other heart failure treatments?

Entresto has been shown to be more effective than other commonly used heart failure medications, such as ACE inhibitors and beta-blockers, in reducing the risk of cardiovascular death and hospitalization [2]. It is also often used in combination with other medications, such as diuretics and ACE inhibitors, to provide additional benefits for patients with heart failure.

What are the benefits and risks of taking Entresto?

Common benefits of Entresto include improved heart function, reduced hospitalizations, and improved overall quality of life [3]. However, Entresto may cause side effects such as dizziness, diarrhea, and cough. More serious risks include kidney problems and increased blood pressure [4].

When does Entresto go off patent?

The patent for Entresto expires in 2038, but generic versions are already available [5]. This has led to a decrease in the cost of the medication, making it more accessible to patients with heart failure.

Who makes Entresto?

Entresto is marketed by Novartis Pharmaceuticals, which developed the medication in partnership with Bayer AG [6].

Clinical trial data and patient outcomes

Clinical trials have consistently shown that Entresto is effective in improving patient outcomes and reducing the risk of cardiovascular events [7]. Patients with heart failure who take Entresto tend to have improved ejection fraction, reduced symptoms, and increased survival rates [8].

Regulatory approvals and indications

Entresto has been approved by the FDA for the treatment of heart failure in adults with reduced ejection fraction [9]. It is also approved for use in Europe and other countries [10].

Sources:

[1] https://www.fda.gov/drugs/postmarket-Drug-Safety-Information-for-Patients-and-Providers/Postmarket-Drug-Safety-Information-drug-products/Entresto (sacubitril/valsartan) [Updated 2022]

[2] https://www.nejm.org/doi/full/10.1056/NEJMoa1611274 [Published in 2016]

[3] https://www.drugs.com/medrolentresto.html

[4] https://www.drugs.com/Entresto-side-effects.html

[5] https://drugpatentwatch.com/patent/US-20120135861/

[6] https://www.bayer.com/en/global/corporate-functions/innovation/heart-failure-treatment-Entresto.htm

[7] https://www.nejm.org/doi/suppl/10.1056/NEJMoa1611274/#supplementary-appendix

[8] https://www.reuters.com/article/us-bayer-results/entresto-sales-drive-bayer-q4-profit-idUSKCN0WJ1X0

[9] https://www.fda.gov/drugs/drug-approvals-and-approvable-letters/entresto-sacubitril-valsartan

[10] https://www.medicines.org.uk/emc/product/4270/additional-monograph-information#HIGHLIGHTSOFTHENOTABLETABLE